| Similar Articles |
|---|
 |
The Motley Fool
February 14, 2011
Brian Orelli |
This Biotech Is Heating Up Biosante Pharmaceuticals was up more than 9% at one point today after the company said the independent Data Monitoring Committee believed Biosante's female sexual dysfunction drug, LibiGel, was safe enough to allow the trial to continue.   |
Chemistry World
August 26, 2015
Sarah Houlton |
Female sexual desire drug approved Almost five years after Boehringer Ingelheim stopped development on the female hypoactive sexual desire disorder treatment flibanserin, it has been approved by the US Food and Drug Administration. |
Chemistry World
June 27, 2013
Phillip Broadwith |
Ups and downs for erectile dysfunction drugs Spedra (avanafil) aims to compete for a share of the lucrative ED market, trading on the fact that it is much faster-acting than other available drugs. |
Chemistry World
November 18, 2009
Sarah Houlton |
A pharmaceutical named desire A new drug being developed by Boehringer Ingelheim could give a boost to the sex drive of women with low libido. |
The Motley Fool
June 17, 2004
Seth Jayson |
P&G Patches Up Sex Life? Proctor & Gamble announced that a second phase 3 clinical trial had demonstrated the safety and efficacy of its testosterone patch, to be called Intrinsa, for treating sexual dysfunction in women. |
The Motley Fool
December 15, 2011
Brian Orelli |
BioSante Shares Crushed by Placebo Effect BioSante's LibiGel efficacy is not deemed statistically significant. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
June 23, 2010
Kris Eddy |
Drugmakers Finally Recognize the Next Big Opportunity Drug companies seem to be increasing efforts to address female health problems. |
Salon.com
October 26, 2000
Barbara Raab |
The vagina dialogues Hundreds of doctors gather in Boston for their annual gabfest about women's sexual dysfunction -- but some of their colleagues say they're misguided... |
The Motley Fool
January 25, 2011
Brian Orelli |
FDA Approved -- Now Will It Sell? There's still plenty of uncertainty in Clinical Data's shares. |
Nurse Practitioner
January 2009
Clair Kaplan |
Assessing & Managing Female Sexual Dysfunction NPs can be important first-line, healthcare providers for women with FSD. |
The Motley Fool
May 25, 2011
Brian Orelli |
Satisfying Clinical Trial Straightens Up Shares VIVUS' erectile dysfunction drug avanafil works. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
August 31, 2011
Brian Orelli |
3 Biotechs Ready to Move Here are three biotechs with upcoming events that could drive their value higher: Exelixis... BioSante Pharmaceuticals... Amylin Pharmaceuticals... |
BusinessWeek
July 2, 2007
Arlene Weintraub |
Lifestyle Drug Binge The huge profits in weight-loss and other treatments makes them hard for drugmakers to resist. But safety risks abound. |
BusinessWeek
January 21, 2010
John Carey |
Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes. |
Salon.com
October 26, 2000
Hank Hyena |
Carnal goo New products now being tested promise to alleviate female sexual dysfunction... |
The Motley Fool
May 31, 2011
Brian Orelli |
Pay Attention, Biotech Investors Competitors and partners can't be ignored. |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
AskMen.com
June 23, 2004
Joshua Levine |
Erection Drugs: Part II Thanks to modern medicine, a man can soon choose from a variety of new erection drugs. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
BusinessWeek
November 29, 2004
Carey & Barrett |
Lessons From The Vioxx Fiasco What drugmakers, the FDA, doctors, and patients need to do. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
August 18, 2010
Brian Orelli |
No Pain Here as Jazz Shares Rocket Investors are all jazzed up about Jazz Pharmaceuticals |
The Motley Fool
April 7, 2011
Brian Orelli |
Restless No Longer XenoPort and Glaxo get a delayed FDA approval. |
BusinessWeek
October 29, 2009
Arlene Weintraub |
Testosterone Is Sure Looking Virile Despite legal setbacks and FDA delays, youth-crazed boomers are making testosterone a billion-dollar industry. |
The Motley Fool
November 15, 2010
Brian Orelli |
A Mega-Blockbuster Showdown Boehringer Ingelheim's Pradaxa was recently approved to treat patients with an erratic heartbeat, and Bayer and Johnson & Johnson have a second compound, Xarelto, that isn't far behind. |
The Motley Fool
June 30, 2010
Brian Orelli |
When Researchers Attack, Investors Lose Drug investors have to watch out for a lot of things that can change their stock's price: earnings reports, clinical trial results, competitor's results, and FDA decisions. |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
American Family Physician
May 15, 2004
Smucny & Park |
Clinical Inquiries From the Family Practice Inquiries Network: Which antidepressant is best to avoid sexual dysfunction? |
The Motley Fool
January 31, 2011
Brian Orelli |
5 Drugmakers Headed Back to the Drawing Board Sometimes an FDA rejection is more of a to-do list. |
Salon.com
June 21, 2000
Kuhn & Wilson |
Dazed and unused In the debut of a new column on drugs, our expert pharmacologists advise a woman on what to do with her stoned boyfriend's lack of interest in sex. |
American Family Physician
July 1, 2000
Nancy A. Phillips |
Female Sexual Dysfunction: Evaluation and Treatment Sexual dysfunction includes desire, arousal, orgasmic and sex pain disorders (dyspareunia and vaginismus). Primary care physicians must assume a proactive role in the diagnosis and treatment of these disorders... |
American Family Physician
August 15, 2000
Robert L. Phillips, Jr. |
Depression and Sexual Desire Asking a depressed patient about libido and sexual function and tailoring treatment to minimize adverse effects on sexual function can significantly increase treatment compliance and improve the quality of the patient's life... |
BusinessWeek
May 8, 2006
Catherine Arnst |
Hey, You Don't Look So Good As diagnoses of once-rare illnesses soar, doctors say drugmakers are "disease-mongering" to boost sales. |
The Motley Fool
May 14, 2008
Brian Lawler |
Teaching Old Drugs New Tricks Pfizer's top drugs post mixed results in recent off-label studies. |
The Motley Fool
June 29, 2010
Brian Orelli |
The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting. |
Wired
July 2005
Annalee Newitz |
The Coming Boom Big Pharma has made billions pumping up the male population. Now neuroscientists are reverse engineering the female orgasm. For women, excitement starts in the brain. |
AskMen.com
February 19, 2015
Christopher Asandra |
The Rate Of Erectile Dysfunction Recently, the Military Times reported that the United States Department of Defense had spent nearly $300 million on drugs to treat erectile dysfunction since 2011. |
Pharmaceutical Executive
March 1, 2012
Ron Cohen |
FDA's Necessary Dose of Reality There's no fast-acting salve, but there are several steps that can be taken to streamline many of the procedures at FDA. And it begins with leadership. |
ifeminists
July 7, 2004
Diana Goss |
An Investigation Into the Prescribing of Drugs for Non-Medical Concerns In the light of new drugs being developed to resolve so-called "female sexual dysfunctions," it has now been clearly identified that female sexuality has been genderised by the way in which those who are analysing it would prefer us all to view this. |
AskMen.com
October 30, 2015
Asandra & Palubicki |
Are Erectile Dysfunction Supplements Dangerous? Here's why erectile dysfunction supplements can be extremely dangerous. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
American Family Physician
July 1, 2000 |
Sex Isn't Working for Me. What Can I Do? When you have problems with sex, doctors call it "sexual dysfunction." Men and women can have it. There are four kinds of sexual problems in women. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
AskMen.com
Dave Golokhov |
Erectile Dysfunction Therapy A study, which was published in The Journal of Sexual Medicine, tested a method called shock therapy, which is normally used to treat kidney stones externally. |
American Family Physician
January 15, 2003
Nusbaum et al. |
Chronic Illness and Sexual Functioning Patients who have chronic illness often have difficulties with sexual functioning. With an understanding of the impact that illness can have on sexual functioning and the use of basic management strategies, family physicians can readily enhance quality of life for their patients. |
Health
September 2006
Afi-Odelia E. Scruggs |
Synchronized Sex One of you wants it, the other doesn't. Time to harmonize your hormones. |
